Annual Accounts Payable
$3.49 M
+$154.00 K+4.61%
31 December 2023
Summary:
Celldex Therapeutics annual accounts payable is currently $3.49 million, with the most recent change of +$154.00 thousand (+4.61%) on 31 December 2023. During the last 3 years, it has risen by +$2.45 million (+233.40%). CLDX annual accounts payable is now -31.64% below its all-time high of $5.11 million, reached on 31 December 2008.CLDX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$1.11 M
-$2.69 M-70.70%
01 September 2024
Summary:
Celldex Therapeutics quarterly accounts payable is currently $1.11 million, with the most recent change of -$2.69 million (-70.70%) on 01 September 2024. Over the past year, it has dropped by -$2.47 million (-68.93%). CLDX quarterly accounts payable is now -78.20% below its all-time high of $5.11 million, reached on 31 December 2008.CLDX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.6% | -68.9% |
| 3 y3 years | +233.4% | +33.3% |
| 5 y5 years | +226.8% | +67.3% |
CLDX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +233.4% | -70.7% | +33.3% |
| 5 y | 5 years | at high | +233.4% | -70.7% | +96.1% |
| alltime | all time | -31.6% | +1647.0% | -78.2% | +1014.0% |
Celldex Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.11 M(-70.7%) |
| June 2024 | - | $3.80 M(+17.6%) |
| Mar 2024 | - | $3.23 M(-7.4%) |
| Dec 2023 | $3.49 M(+4.6%) | $3.49 M(-2.6%) |
| Sept 2023 | - | $3.59 M(+307.0%) |
| June 2023 | - | $881.00 K(-73.9%) |
| Mar 2023 | - | $3.37 M(+1.0%) |
| Dec 2022 | $3.34 M(+172.0%) | $3.34 M(+47.0%) |
| Sept 2022 | - | $2.27 M(+151.9%) |
| June 2022 | - | $902.00 K(-11.5%) |
| Mar 2022 | - | $1.02 M(-17.0%) |
| Dec 2021 | $1.23 M(+17.2%) | $1.23 M(+46.9%) |
| Sept 2021 | - | $836.00 K(+22.0%) |
| June 2021 | - | $685.00 K(-31.3%) |
| Mar 2021 | - | $997.00 K(-4.9%) |
| Dec 2020 | $1.05 M(-10.7%) | $1.05 M(+84.5%) |
| Sept 2020 | - | $568.00 K(-40.2%) |
| June 2020 | - | $950.00 K(-41.0%) |
| Mar 2020 | - | $1.61 M(+37.1%) |
| Dec 2019 | $1.17 M(+9.8%) | $1.17 M(+76.3%) |
| Sept 2019 | - | $666.00 K(-34.4%) |
| June 2019 | - | $1.02 M(-8.1%) |
| Mar 2019 | - | $1.10 M(+3.4%) |
| Dec 2018 | $1.07 M(-37.7%) | $1.07 M(-53.7%) |
| Sept 2018 | - | $2.31 M(-21.4%) |
| June 2018 | - | $2.94 M(+479.1%) |
| Mar 2018 | - | $508.00 K(-70.4%) |
| Dec 2017 | $1.72 M(-1.4%) | $1.72 M(+34.2%) |
| Sept 2017 | - | $1.28 M(-35.3%) |
| June 2017 | - | $1.98 M(-25.8%) |
| Mar 2017 | - | $2.66 M(+52.9%) |
| Dec 2016 | $1.74 M(+15.5%) | $1.74 M(+70.8%) |
| Sept 2016 | - | $1.02 M(+44.3%) |
| June 2016 | - | $706.00 K(-73.2%) |
| Mar 2016 | - | $2.64 M(+75.1%) |
| Dec 2015 | $1.51 M(-42.1%) | $1.51 M(+23.7%) |
| Sept 2015 | - | $1.22 M(-39.8%) |
| June 2015 | - | $2.02 M(-34.2%) |
| Mar 2015 | - | $3.07 M(+18.0%) |
| Dec 2014 | $2.60 M(+16.0%) | $2.60 M(+51.3%) |
| Sept 2014 | - | $1.72 M(+44.9%) |
| June 2014 | - | $1.19 M(-65.2%) |
| Mar 2014 | - | $3.41 M(+52.2%) |
| Dec 2013 | $2.24 M(+201.1%) | $2.24 M(+13.2%) |
| Sept 2013 | - | $1.98 M(-4.2%) |
| June 2013 | - | $2.07 M(-15.6%) |
| Mar 2013 | - | $2.45 M(+229.0%) |
| Dec 2012 | $745.00 K(-20.3%) | $745.00 K(-41.8%) |
| Sept 2012 | - | $1.28 M(+224.3%) |
| June 2012 | - | $395.00 K(-26.2%) |
| Mar 2012 | - | $535.00 K(-42.8%) |
| Dec 2011 | $935.00 K(+0.4%) | $935.00 K(+104.6%) |
| Sept 2011 | - | $457.00 K(-11.1%) |
| June 2011 | - | $514.00 K(-30.4%) |
| Mar 2011 | - | $738.00 K(-20.7%) |
| Dec 2010 | $931.00 K(-35.6%) | $931.00 K(+25.6%) |
| Sept 2010 | - | $741.00 K(-30.9%) |
| June 2010 | - | $1.07 M(-33.6%) |
| Mar 2010 | - | $1.62 M(+11.9%) |
| Dec 2009 | $1.45 M(-71.7%) | $1.45 M(-64.8%) |
| Sept 2009 | - | $4.11 M(-5.1%) |
| June 2009 | - | $4.33 M(-2.8%) |
| Mar 2009 | - | $4.45 M(-12.8%) |
| Dec 2008 | $5.11 M(+581.6%) | $5.11 M(+263.6%) |
| Sept 2008 | - | $1.41 M(+5.7%) |
| June 2008 | - | $1.33 M(-29.3%) |
| Mar 2008 | - | $1.88 M(+150.7%) |
| Dec 2007 | $749.90 K | $749.90 K(-26.7%) |
| Sept 2007 | - | $1.02 M(+15.2%) |
| June 2007 | - | $887.60 K(-12.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2007 | - | $1.02 M(-60.1%) |
| Dec 2006 | $2.55 M(+123.8%) | $2.55 M(+207.1%) |
| Sept 2006 | - | $831.10 K(+25.7%) |
| June 2006 | - | $661.30 K(+10.5%) |
| Mar 2006 | - | $598.50 K(-47.5%) |
| Dec 2005 | $1.14 M(-34.9%) | $1.14 M(+139.2%) |
| Sept 2005 | - | $476.90 K(-22.7%) |
| June 2005 | - | $617.20 K(-45.7%) |
| Mar 2005 | - | $1.14 M(-35.2%) |
| Dec 2004 | $1.75 M(+268.3%) | $1.75 M(+169.4%) |
| Sept 2004 | - | $650.40 K(+111.2%) |
| June 2004 | - | $307.90 K(-27.9%) |
| Mar 2004 | - | $427.30 K(-10.2%) |
| Dec 2003 | $475.80 K(-43.1%) | $475.80 K(+83.6%) |
| Sept 2003 | - | $259.10 K(+38.5%) |
| June 2003 | - | $187.10 K(-46.4%) |
| Mar 2003 | - | $349.00 K(-58.3%) |
| Dec 2002 | $836.00 K(-26.0%) | $836.00 K(+68.3%) |
| Sept 2002 | - | $496.80 K(-16.1%) |
| June 2002 | - | $592.30 K(+129.2%) |
| Mar 2002 | - | $258.40 K(-77.1%) |
| Dec 2001 | $1.13 M(+25.2%) | $1.13 M(+29.4%) |
| Sept 2001 | - | $872.70 K(+42.3%) |
| June 2001 | - | $613.10 K(+60.7%) |
| Mar 2001 | - | $381.60 K(-57.7%) |
| Dec 2000 | $902.30 K(+56.8%) | $902.30 K(+24.9%) |
| Sept 2000 | - | $722.40 K(+181.7%) |
| June 2000 | - | $256.40 K(-29.2%) |
| Mar 2000 | - | $362.40 K(-37.0%) |
| Dec 1999 | $575.30 K(+43.8%) | $575.30 K(+475.3%) |
| Sept 1999 | - | $100.00 K(0.0%) |
| June 1999 | - | $100.00 K(-85.7%) |
| Mar 1999 | - | $700.00 K(+75.0%) |
| Dec 1998 | $400.00 K(+100.0%) | $400.00 K(+100.0%) |
| Sept 1998 | - | $200.00 K(-33.3%) |
| June 1998 | - | $300.00 K(+50.0%) |
| Mar 1998 | - | $200.00 K(0.0%) |
| Dec 1997 | $200.00 K(-33.3%) | $200.00 K(-33.3%) |
| Sept 1997 | - | $300.00 K(0.0%) |
| June 1997 | - | $300.00 K(0.0%) |
| Mar 1997 | - | $300.00 K(0.0%) |
| Dec 1996 | $300.00 K(-57.1%) | $300.00 K(+200.0%) |
| Sept 1996 | - | $100.00 K(-50.0%) |
| June 1996 | - | $200.00 K(0.0%) |
| Mar 1996 | - | $200.00 K(-71.4%) |
| Dec 1995 | $700.00 K(-12.5%) | $700.00 K(-12.5%) |
| Sept 1995 | - | $800.00 K(-27.3%) |
| June 1995 | - | $1.10 M(+37.5%) |
| Mar 1995 | - | $800.00 K(0.0%) |
| Dec 1994 | $800.00 K(+60.0%) | $800.00 K(+33.3%) |
| Sept 1994 | - | $600.00 K(-33.3%) |
| June 1994 | - | $900.00 K(+28.6%) |
| Mar 1994 | - | $700.00 K(+40.0%) |
| Dec 1993 | $500.00 K(+25.0%) | $500.00 K(-16.7%) |
| Sept 1993 | - | $600.00 K(+100.0%) |
| June 1993 | - | $300.00 K(0.0%) |
| Mar 1993 | - | $300.00 K(0.0%) |
| Dec 1992 | $400.00 K(+100.0%) | - |
| Oct 1992 | - | $300.00 K(+200.0%) |
| July 1992 | - | $100.00 K(-50.0%) |
| Apr 1992 | - | $200.00 K(-50.0%) |
| Apr 1992 | $200.00 K(-60.0%) | - |
| Oct 1991 | - | $400.00 K(+33.3%) |
| July 1991 | - | $300.00 K(-40.0%) |
| Apr 1991 | $500.00 K(-37.5%) | $500.00 K(0.0%) |
| Jan 1991 | - | $500.00 K(+25.0%) |
| Oct 1990 | - | $400.00 K(-20.0%) |
| July 1990 | - | $500.00 K(-37.5%) |
| Apr 1990 | $800.00 K | $800.00 K(+100.0%) |
| Jan 1990 | - | $400.00 K |
FAQ
- What is Celldex Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Celldex Therapeutics?
- What is Celldex Therapeutics annual accounts payable year-on-year change?
- What is Celldex Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly accounts payable year-on-year change?
What is Celldex Therapeutics annual accounts payable?
The current annual accounts payable of CLDX is $3.49 M
What is the all time high annual accounts payable for Celldex Therapeutics?
Celldex Therapeutics all-time high annual accounts payable is $5.11 M
What is Celldex Therapeutics annual accounts payable year-on-year change?
Over the past year, CLDX annual accounts payable has changed by +$154.00 K (+4.61%)
What is Celldex Therapeutics quarterly accounts payable?
The current quarterly accounts payable of CLDX is $1.11 M
What is the all time high quarterly accounts payable for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly accounts payable is $5.11 M
What is Celldex Therapeutics quarterly accounts payable year-on-year change?
Over the past year, CLDX quarterly accounts payable has changed by -$2.47 M (-68.93%)